Intuitive Surgical Inc (ISRG) Stock Price & Analysis
Intuitive Surgical Inc (ISRG) rose 1.65% to USD 337.5 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
ISRG last closed at USD 332.02; the session ranged USD 332.25–341.78 on volume of 3,436,653 shares. Market capitalization is $120.92B, with a 52-week range of USD 328.57–603.88 (NMS). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 337.5 |
|---|---|
| Change | ▲ 1.65% (up) |
| Previous Close | USD 332.02 |
| Open | USD 334.6 |
| Day Range | USD 332.25 – 341.78 |
| 52-Week Range | USD 328.57 – 603.88 |
| Volume | 3,436,653 shares |
| Market Cap | $120.92B |
| Exchange | NMS |
Technical Analysis (ISRG)
Nexqual's technical model rates ISRG "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.07 (neutral) |
| vs SMA50 | Below (USD 407.09) |
| MACD | -20.41 (negative) |
Analyst Ratings (ISRG)
Wall Street analysts rate ISRG "Buy" based on 28 analysts, with a mean price target of USD 484.4 (range USD 324–685), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 28 |
| Mean Target | USD 484.4 |
| High Target | USD 685 |
| Low Target | USD 324 |
| Buy / Hold / Sell | 22 / 9 / 1 |
Earnings (ISRG)
| Next Earnings Date | 2026-10-20 |
|---|---|
| EPS Estimate | USD 2.63 |
| Revenue Estimate | $2.90B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.8 vs est 2.5 ▲ beat |
| 2026-03-31 | USD 2.5 vs est 2.11 ▲ beat |
| 2025-12-31 | USD 2.53 vs est 2.27 ▲ beat |
| 2025-09-30 | USD 2.4 vs est 1.99 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (ISRG)
| Total Revenue | $11.03B |
|---|---|
| Revenue Growth (YoY) | +18.50% |
| Gross Margin | +66.68% |
| Operating Margin | +33.60% |
| Profit Margin | +28.45% |
| ROE | +17.42% |
| Current Ratio | 4.96 |
| Total Cash | $5.22B |
| Total Debt | $0 |
| Free Cash Flow | $2.62B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (ISRG)
Nexqual rates Intuitive Surgical Inc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 67%, operating 34% |
| Balance Sheet | Mixed — $5.22B cash, no debt |
| Cash Flow | Strong — FCF $2.62B, 26% margin |
| Efficiency | Solid — ROE 17%, ROA 10.5% |
Ownership (ISRG)
| Insider Ownership | +0.51% |
|---|---|
| Institutional Ownership | +91.50% |
| Shares Outstanding | 358.28M |
| Float | 351.21M |
| Short % of Float | +2.08% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (ISRG)
Intuitive Surgical Inc is led by David J. Rosa (age 57), CEO & Director, per Nexqual as of July 25, 2026 at 01:12 UTC.
| CEO & Director | David J. Rosa (age 57) |
|---|---|
| Executive VP, CFO & Enterprise Technology Leader | Jamie E. Samath (age 54) |
| Executive Vice President of Research, Corporate Development, Corporate Strategy & Intuitive Ventures | Christopher R. Carlson |
Major Backers & Investors (ISRG)
Notable institutional backers of Intuitive Surgical Inc include Invesco, Price (T.Rowe) Associates Inc, Capital Group, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 5.3% |
| Price (T.Rowe) Associates Inc | 3.54% |
| Capital Group | 2.28% |
| Morgan Stanley | 1.72% |
| FMR, LLC | 1.55% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.41% |
| BlackRock | 9.83% |
| State Street | 5.7% |
| Geode Capital | 2.4% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Intuitive Surgical Inc's Latest SEC 10-K Filing (filed 2026-02-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
- It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
- It sells its products through direct sales organizations, such as capital and clinical sales teams.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorpor | USD 477.36 | ▲ 1.01% |
| NOW | ServiceNow, Inc. | USD 98.78 | ▲ 3.48% |
| CRM | Salesforce, Inc. | USD 163.66 | ▲ 0.4% |
| ILMN | Illumina, Inc. | USD 194.09 | ▲ 1.69% |
| LRCX | Lam Research Corporation | USD 305.21 | ▼ 4.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.